Stonepine Capital, L.p. - Net Worth and Insider Trading

Stonepine Capital, L.p. Net Worth

The estimated net worth of Stonepine Capital, L.p. is at least $25 Million dollars as of 2024-05-16. Stonepine Capital, L.p. is the 10% Owner of Apollo Endosurgery Inc and owns about 2,185,426 shares of Apollo Endosurgery Inc (APEN) stock worth over $22 Million. Stonepine Capital, L.p. is also the 10% Owner of Novelion Therapeutics Inc and owns about 3,909,207 shares of Novelion Therapeutics Inc (NVLNF) stock worth over $3 Million. Details can be seen in Stonepine Capital, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Stonepine Capital, L.p. has not made any transactions after 2019-12-12 and currently still holds the listed stock(s).

Transaction Summary of Stonepine Capital, L.p.

To

Stonepine Capital, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Stonepine Capital, L.p. owns 3 companies in total, including Novelion Therapeutics Inc (NVLNF) , Apollo Endosurgery Inc (APEN) , and Viveve Medical Inc (VIVE) .

Click here to see the complete history of Stonepine Capital, L.p.’s form 4 insider trades.

Insider Ownership Summary of Stonepine Capital, L.p.

Ticker Comapny Transaction Date Type of Owner
NVLNF Novelion Therapeutics Inc 2019-12-12 10 percent owner
APEN Apollo Endosurgery Inc 2018-12-27 10 percent owner
VIVE Viveve Medical Inc 2015-05-14 10 percent owner

Stonepine Capital, L.p. Latest Holdings Summary

Stonepine Capital, L.p. currently owns a total of 2 stocks. Among these stocks, Stonepine Capital, L.p. owns 2,185,426 shares of Apollo Endosurgery Inc (APEN) as of December 27, 2018, with a value of $22 Million and a weighting of 88.84%. Stonepine Capital, L.p. also owns 3,909,207 shares of Novelion Therapeutics Inc (NVLNF) as of December 12, 2019, with a value of $3 Million and a weighting of 11.16%.

Latest Holdings of Stonepine Capital, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
APEN Apollo Endosurgery Inc 2018-12-27 2,185,426 10.00 21,854,260
NVLNF Novelion Therapeutics Inc 2019-12-12 3,909,207 0.70 2,744,263

Holding Weightings of Stonepine Capital, L.p.


Stonepine Capital, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Stonepine Capital, L.p. has made a total of 0 transactions in Apollo Endosurgery Inc (APEN) over the past 5 years. The most-recent trade in Apollo Endosurgery Inc is the sale of 250,000 shares on December 27, 2018, which brought Stonepine Capital, L.p. around $750,000.

According to the SEC Form 4 filings, Stonepine Capital, L.p. has made a total of 4 transactions in Novelion Therapeutics Inc (NVLNF) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Novelion Therapeutics Inc is the acquisition of 6,242 shares on December 12, 2019, which cost Stonepine Capital, L.p. around $4,307.

Insider Trading History of Stonepine Capital, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Stonepine Capital, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Stonepine Capital, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Stonepine Capital, L.p. is 4.14%. GuruFocus also compares Stonepine Capital, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Stonepine Capital, L.p. within 3 months outperforms 4 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Stonepine Capital, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Stonepine Capital, L.p.

Average Return

Average return per transaction

Outperforming Transactions

0 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 2.91
Relative Return to S&P 500(%) 0.9

Stonepine Capital, L.p. Ownership Network

Ownership Network List of Stonepine Capital, L.p.

No Data

Ownership Network Relation of Stonepine Capital, L.p.


Stonepine Capital, L.p. Owned Company Details

What does Novelion Therapeutics Inc do?

Who are the key executives at Novelion Therapeutics Inc?

Stonepine Capital, L.p. is the 10 percent owner of Novelion Therapeutics Inc. Other key executives at Novelion Therapeutics Inc include 10 percent owner Broadfin Healthcare Master Fund Ltd , 10 percent owner Broadfin Capital, Llc , and 10 percent owner Kevin Kotler .

Novelion Therapeutics Inc (NVLNF) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Novelion Therapeutics Inc (NVLNF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Novelion Therapeutics Inc (NVLNF) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Novelion Therapeutics Inc (NVLNF)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Novelion Therapeutics Inc Insider Transactions

No Available Data

Stonepine Capital, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Stonepine Capital, L.p.. You might contact Stonepine Capital, L.p. via mailing address: 919 Nw Bond Street, Suite 204, Bend Or 97703.

Discussions on Stonepine Capital, L.p.

No discussions yet.